Targeted radioimmunotherapy for acute myeloid leukemia using antibodies to active integrin β2
Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2
A targeted radioimmunotherapy uses an antibody to deliver radiation directly to AML cells with an active form of integrin β2, aiming to treat people with acute myeloid leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11299580 on NIH RePORTER |
What this research studies
This project builds on a novel antibody (clone 7065) that recognizes the active, open shape of integrin β2 found on many AML cells. The team will attach that antibody to the alpha-particle emitter actinium-225 to create a radioimmunotherapy that delivers potent, localized radiation to leukemia cells. Work includes laboratory and preclinical testing of targeting, toxicity, and anti-leukemia activity, with comparisons to other AML targets. If the results support safety and effectiveness, the researchers plan steps toward treating people at UCSF in future clinical trials.
Who could benefit from this research
Good fit: Ideal candidates would be people with acute myeloid leukemia—especially relapsed or refractory cases—whose leukemia cells express the active conformation of integrin β2.
Not a fit: People whose leukemia does not show the active integrin β2 marker or who cannot tolerate radioactive therapies (for example due to poor organ function or pregnancy) are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could kill AML cells more precisely while reducing damage to healthy cells, potentially improving outcomes and safety.
How similar studies have performed: Related radioimmunotherapies have been FDA-approved for other cancers and prior lab work with this antibody in CAR-T models showed promising safety and activity, but applying actinium-225 RIT to AML is a novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Wiita, Arun P. — University of California, San Francisco
- Study coordinator: Wiita, Arun P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.